Clinical Trial Update: Regorafenib for Recurrent Meningioma (MIRAGE Trial) [Phase 2]

View source ↗

Summary

The MIRAGE trial is a Phase 2 study evaluating regorafenib for recurrent malignant meningioma and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningioma Malignant

Drugs mentioned

• Regorafenib (regorafenib)

Snippet

Sponsor: Istituto Oncologico Veneto IRCCS | Conditions: Meningioma, Malignant | Phase 2 | Status: RECRUITING